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Research
Breast cancer etiology attributed to heredi-
tary causes is low, accounting for an esti-
mated 5–15% of all diagnosed cases (Colditz 
and Frazier 1995). Extrinsic factors, such as 
environ  ment and lifestyle, may play substan-
tial roles in the high incidence of breast cancer. 
Routine exposures to certain environ  mental 
contaminants, especially those with the abil-
ity to alter endocrine signaling, are currently 
being scrutinized for their potential roles in 
breast cancer causation. One such example 
can be found in the synthetic estrogen diethyl-
stilbestrol (DES). Women were prescribed 
DES from 1947 until 1971 to prevent miscar-
riages. Not only was the drug therapeutically 
ineffective, but reports have established that 
women exposed in utero to DES showed an 
increased incidence of a rare type of vaginal 
cancer and an increased risk of developing 
breast cancer (Herbst et al. 1999; Troisi et al. 
2007). These effects, occurring more than a 
decade after the original exposure, have caused 
greater public awareness of the role of early 
endocrine-disruptor exposure in lifetime breast 
cancer susceptibility. Likewise, recent media 
attention has focused on another common 
environmental endocrine disruptor, bisphenol 
A (BPA), as a potentially harmful chemical 
because of its widespread exposure to humans 
and reported endocrine-disruptor activity.
BPA is ubiquitous in modern society. The 
main source of BPA stems from its widespread 
use to manufacture polycarbonate plastic and 
epoxy resins used in beverage and food con-
tainers, infant formula bottles, canned food 
liners, and some dental sealants, among other 
uses. However, the bonds that connect the 
BPA monomers are weak and highly subject 
to degradation even with normal use (Le et al. 
2008). Factors such as time, higher tempera-
tures, and pH extremes accelerate this process 
(Kang et al. 2003).
Calafat et al. (2005) found that 95% 
of adults surveyed (n = 394) had detectable 
concentrations of total (free plus conjugated) 
urinary BPA. In a pilot study of the concentra-
tions of a panel of environmental chemicals in 
the urine of young girls, Wolff et al. (2007) 
reported similar findings. They reported total 
BPA concentrations ranging from below the 
limit of detection (0.3 µg BPA/L) to 54.3 µg 
BPA/L, with an average value of 2.0 µg BPA/L 
(3.0 µg BPA/g creatinine). A large-scale investi-
gation supported these previous studies (Calafat 
et al. 2008), finding detectable concentrations 
of total BPA in 93% of > 2,000 participants, 
averaging 2.6 µg BPA/L. Furthermore, concen-
trations of total BPA increased with decreasing 
age. Children (6–11 years of age) had the high-
est concentrations of total BPA [least square 
geometric mean (LSGM), 4.5 µg BPA/L], sig-
nificantly higher than those of adults (LSGM, 
2.5 µg BPA/L) (Calafat et al. 2008). BPA has 
been found to leach from polycarbonate infant 
formula bottles and as free and conjugated 
forms in breast milk, suggesting several sources 
for early BPA exposure and creating the con-
cern that long-lasting adverse health effects 
may arise as a consequence (Brede et al. 2003; 
Sun et al. 2004; Ye et al. 2006).
Several studies using animal models have 
linked early exposure to BPA with develop-
mental and reproductive abnormalities in 
both sexes (Ho et al. 2006; Howdeshell 
et al. 1999). Perinatal exposure to BPA at 
0.1 or 1.2 mg/kg body weight (bw) per day 
through drinking water significantly increased 
body weight, altered estrous cyclicity, and 
significantly lowered plasma concentrations 
of luteinizing hormone (Rubin et al. 2001). 
Perinatal exposure to BPA at 250 ng/kg bw/day 
through an osmotic pump caused significant 
alterations in the mammary gland, including an 
increased number of terminal end buds (TEBs), 
decreased apoptosis in TEBs, an increased per-
centage of cells expressing the progesterone 
receptor (PR), and increased lateral branching 
(Munoz-de-Toro et al. 2005). With gestational 
exposure alone, BPA advanced puberty and 
increased the number of terminal ducts, TEBs, 
alveolar buds, and pre  neoplastic lesions in the 
mammary gland (Markey et al. 2001; Murray 
et al. 2007). These and other studies provide a 
substantial amount of evidence to warrant fur-
ther investigation into the potential deleterious 
effects caused by early exposure to BPA, espe-
cially in terms of mammary carcinogenesis.
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Ba c k g r o u n d: Bisphenol A (BPA) is widely used in the manufacture of polycarbonate plastics, 
including infant formula bottles.
oBjectives: Based on the reported endocrine disruptor activity of this polyphenol, we hypothesized 
that exposure to BPA early in life would elicit developmental changes in the mammary tissue and 
cause a predisposition for mammary cancer.
me t h o d s : We exposed neonatal/prepubertal rats to BPA via lactation from nursing dams treated 
orally with 0, 25, and 250 µg BPA/kg body weight/day. For tumorigenesis studies, female offspring 
were exposed to 30 mg dimethylbenzanthracene (DMBA)/kg body weight at 50 days of age.
re s u l t s: The combination of DMBA treatment with lactational exposure to BPA demonstrated 
a dose-dependent increase in mammary tumor multiplicity and reduced tumor latency compared 
with controls. In the absence of DMBA treatment, lactational BPA exposure resulted in increased 
cell proliferation and decreased apoptosis at 50 but not 21 days post  partum (shortly after last 
BPA treatment). Using Western blot analysis, we determined that steroid receptor coactivators 
(SRCs) 1–3, Akt, phosphorylated Akt, progesterone receptor A (PR-A), and erbB3 proteins were 
significantly up-regulated at 50 days of age. 
co n c l u s i o n s: The data presented here provide the first evidence that maternal exposure to BPA 
during lactation increases mammary carcinogenesis in a DMBA-induced model of rodent mammary 
cancer. Changes in PR-A, SRC 1–3, erbB3, and Akt activity are consistent with increased cell pro-
liferation and decreased apoptosis playing a role in mammary cancer susceptibility. These alterations 
provide an explanation of enhanced mammary carcinogenesis after lactational BPA exposure.
key w o r d s : apoptosis, bisphenol A, mammary cancer, proliferation, steroid receptor coactivators. 
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We sought to determine whether early 
exposure to BPA could accelerate mammary 
carcinogenesis in a dimethyl  benzanthracene 
(DMBA) model of rodent mammary cancer. 
We treated lactating dams with low concentra-
tions of BPA: 25 µg/kg/day, which is one-half 
of the U.S. Environmental Protection Agency’s 
(EPA) daily oral reference dose of 50 µg/kg/
day (BPA 25 group), and 250 µg/kg/day, 
which is 200-fold less than the lowest observed 
adverse effect level (LOAEL) of 50 mg/kg/
day (BPA 250 group) (National Toxicology 
Program 1982). Thus, the present study pro-
vides the first evidence that oral administration 
of low concentrations of BPA to lactating dams 
can increase mammary cancer susceptibility 
of the female offspring in a DMBA-induced 
model. Our data suggest that the mechanism of 
action behind this response is mediated through 
increased cell proliferation and decreased apop-
tosis and centers on an up-regulation of steroid 
receptor coactivator (SRC) proteins, erbB3, and 
Akt signaling in the mammary gland.
Materials and Methods
Animals. Animal care and use were conducted 
according to established guidelines approved 
by the Institutional Animal Care and Use 
Committee at the University of Alabama at 
Birmingham. Animals were treated humanely 
and with regard for alleviation of suffering. 
All animals were housed in a temperature- 
controlled facility with a 12 hr light/dark cycle. 
Female Sprague Dawley CD rats (Charles 
River, Raleigh, NC) were bred and observed for 
the presence of sperm. Sperm-positive females 
were separated, housed in polypropylene cages 
with glass water bottles (both polycarbonate/
BPA free), and fed phyto  estrogen-free AIN-
93G pelleted diet (Harlan Teklad Global 
Diets, Wilmington, DE). On day 2 post-
partum, all female offspring (5–8) and enough 
males to yield 10 offspring/litter were retained. 
Beginning on postpartum day 2 and continuing 
through postpartum day 20, the lactating dam 
of each litter was intragastrically gavaged with 
sesame oil vehicle (SO) or with BPA at 25 µg/
kg/day (BPA 25) or 250 µg/kg/day (BPA 250) 
on Monday through Friday only (a total of 
15 treatments). Because dam treatment for lac-
tational exposure results in a single exposure 
group per treatment, we used only one offspring 
from each litter in each experiment.
Chemicals. We purchased BPA and sesame 
oil from Sigma Chemical Co. (St. Louis, MO). 
We purchased anti  bodies to erbB2, Bax, phos-
phorylated Bad, Bcl-2, caspase 2, caspase 3, 
and cleaved caspase 3 from Cell Signaling 
(Danvers, MA); anti  bodies to erbB3, estrogen 
receptor-α (ER-α), and PR-A and PR-B from 
Santa Cruz Biotechnology (Santa Cruz, CA); 
and anti  bodies to SRC-1, SRC-2/TIF2, and 
SRC-3/AIB1 from Becton, Dickenson and 
Company (Franklin Lakes, NJ).
Tumorigenesis study. At 50 days of age, 
one female offspring from each litter of each 
treatment group was given a single gavage of 
DMBA 30 mg/kg bw. This dose results in a 
low number of mammary tumors and allows 
chemicals that predispose for mammary cancer 
to increase the number of mammary adeno-
carcinomas (Brown et al. 1998). Because dam 
treatment for lactational exposure results in a 
single exposure group per treatment, we used 
only one offspring from each litter in each 
experiment. There were 32, 34, and 24 female 
offspring in the SO, BPA 25, and BPA 250 
groups, respectively, all derived from individual 
litters. We palpated animals twice weekly to 
monitor tumor development and recorded data 
on palpable tumor latency, location, tumor 
burden, and multiplicity. Animals underwent 
necropsy at 12 months of age or when tumor 
burden exceeded 10% of body weight. All 
tumors and gross lesions were dissected out, 
fixed in formalin, and embedded in paraffin, 
and sections were prepared for pathologic eval-
uation. Coded slides were classified as to tumor 
type, tissue of origin, and degree of invasive-
ness by a board-certified pathologist (I.E.). 
Histopathologic charac  terization of mammary 
neoplastic lesions included carcinoma grade, 
proliferation index, and malignancy evalua-
tions, as described by Meyer et al. (2005).
Mammary dissections. When animals were 
21 and 50 days of age, we processed two sets 
of identically treated rats using ketamine/
xylazine anesthesia for live collection of mam-
mary glands. The fourth abdominal mammary 
glands were collected from each rat; one set of 
the mammary glands was snap frozen in liquid 
nitrogen for immunoblotting (n = 8 per treat-
ment group), and the contralateral glands were 
fixed in formalin and embedded in paraffin 
(n = 5 per treatment group). At 50 days of age, 
all females were killed during the estrous phase.
Hormone concentration. At 50 days of 
age, female offspring lactationally exposed via 
dams treated with BPA 250 or an equal vol-
ume of sesame oil were decapitated and trunk 
blood was collected. We measured serum 
17β-estradiol and progesterone concentrations 
using radio  immuno  assays (Diagnostic Systems 
Laboratories, Webster, TX) as described by the 
manufacturer. All samples were run in dupli-
cate, with eight samples per group, by J. Mahan 
(Obstetrics and Gynecology Department, 
University of Alabama at Birmingham).
Immunohistochemical staining. To deter-
mine cell proliferation, tissue blocks were 
sectioned at 5 µm and placed on glass slides. 
The slides were deparaffinized and rehydrated 
through xylene and graded alcohol washes. 
Slides were boiled in citrate buffer for 15 min, 
incubated in hydrogen peroxide to quench 
endogenous peroxidases, and blocked using 
the appropriate serum. We incubated the slides 
in Ki-67 primary antibody (Dako, Glostrup, 
Denmark) overnight in a humidified cham-
ber. After incubating the tissue sections in the 
appropriate conjugated secondary antibody, we 
employed the use of the ImmPRESS kit (Vector 
Laboratories, Burlingame, CA). Positively 
stained cells were visualized by incubating the 
tissue sections with 3,3´-diamonobenzidine and 
counterstained with hematoxylin. Tissue sec-
tions were dehydrated with graded alcohols, 
cleared with xylene, and mounted with a glass 
coverslip. We used five biologically distinct 
samples derived from individual litters, and 
counted a minimum of three TEB structures 
per slide. We assessed cell proliferation by not-
ing intense nuclear staining for Ki-67 protein.
Apoptosis assay. We determined the rate of 
apoptosis using the ApopTag Plus Peroxidase 
In Situ Apoptosis Detection kit (Chemicon 
International, Billerica, MA) according to the 
manufacturer’s protocol. This method detects 
the apoptotic cells by the indirect TUNEL 
(terminal deoxy  nucleo  tidyl transferase dUTP 
nick end labeling) method. Cells that stained 
positively and exhibited morphologic charac-
teristics of apoptosis were counted as positive. 
We used five biologically distinct samples per 
treatment and counted a minimum of three 
TEB structures per slide.
Immunoblotting. We diced whole mam-
mary glands and homogenized them in RIPA 
lysis buffer (Pierce Biotechnolgy, Rockford, 
IL) using a pestle and sample-grinding kit (GE 
Healthcare Inc., Piscataway, NJ). After homog-
enization, the samples were centrifuged for 
20 min at 16,000 × g at 4°C. We quantified 
protein lysate recovered from the residual tissue 
using the Bradford assay (Bio-Rad Laboratories, 
Hercules, CA). Equal protein content (40 µg) 
was loaded onto precast sodium dodecyl sul-
fate (SDS) Tris-HCl 4–20% poly  acrylamide 
gels (Bio-Rad). Proteins were wet transferred 
to a nitro  cellulose membrane overnight. The 
membrane was blocked at room temperature, 
and the primary antibody was added and 
incubated overnight at 4°C. Secondary anti-
body and chemilume (Pierce Biotechnology, 
Rockford, IL) were added and protein expres-
sion was visualized using film exposures. We 
assessed densitometry patterns using Quantity 
One computer software (Bio-Rad). We used 
positive protein controls purchased from the 
supplier for the corresponding antibodies 
and Kaleidoscope Precision Plus protein and 
prestained SDS-PAGE Broad Range standards 
(Bio-Rad) to identify the protein of interest.
Statistical methods. We analyzed the 
time-to-event data [e.g., time-to-first-tumor 
(latency) and time-to-sacrifice (tumor bur-
den)] using the LIFETEST and LIFEREG 
procedures in SAS (SAS Institute Inc., Cary, 
NC). We first estimated survival functions for 
each group using the Kaplan-Meier method; 
we then compared these across the three 
groups using the Wilcoxon log-rank test, Jenkins et al.
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and parametrically using survival regression 
analysis (Collette 2003). Those animals that 
had not developed a tumor by the end of the 
study or that were sacrificed were censored, 
with either the sacrifice time or the end of 
study treated as censoring times. We analyzed 
tumor multiplicity data with the GENMOD 
(generalized linear models) procedure in SAS 
using generalized Poisson regression on the 
tumor appearance rates (assuming a nega-
tive binomial distribution) (McCullagh and 
Nelder 1989). Because there was a positive 
correlation between number of tumors and 
number of days in the study, we performed 
the tests on multi  plicity after adjusting for 
the number of days each animal was in the 
study. Values for multiplicity are expressed as 
mean ± SE. For cell prolifera  tion and apopto-
sis, the resulting values (stained vs. unstained 
cells) were used to construct a contingency 
table. We tested Western blots for equal vari-
ance using a two-sample F-test, and we used 
the appropriate (assuming equal or unequal 
variance) two-sample t-test. We considered 
p-values ≤ 0.05 to be statistically significant.
Results
Female rats in the BPA 25 and BPA 250 
groups had similar body weights compared 
with the SO group at 2, 7, 14, 21, 35, 50, and 
100 days of age. Puberty, as measured by the 
age at vaginal opening, was not significantly 
altered, occurring on days 31.39 ± 0.24, 31.15 
± 0.21, and 31.88 ± 0.14 for SO, BPA 25, and 
BPA 250 groups, respectively. At 50 days of 
age, serum 17β-estradiol concentration was 
34.4 ± 2.7 and 23.6 ± 4.7 pg/mL for the SO 
and BPA 250 groups, respectively. Circulating 
progesterone concentrations were 12.5 ± 2.8 
and 9.9 ± 1.9 ng/mL in 50-day-old rats in the 
SO and BPA 250 groups, respectively. Neither 
of these findings was significantly different. We 
investigated estrous cyclicity in adult female 
offspring from all three treatment groups for 
19 consecutive days, starting at 7–8 weeks of 
age, and found no significant difference.
DMBA-induced mammary carcino  genesis. 
Female rats in the SO, BPA 25, and BPA 250 
groups gavaged at day 50 with DMBA exhib-
ited a BPA dose-dependent increase in mam-
mary tumors: 2.84 ± 0.31, 3.82 ± 0.43, and 
5.00 ± 0.88 mammary tumors per rat, respec-
tively (Figure 1). After adjusting for the length 
of time on the study (time before sacrifice), we 
found that the BPA 250 group had a signifi-
cantly greater number of tumors per rat than 
did the control group (p = 0.004). Treatment 
with BPA also significantly reduced tumor 
latency, with median tumor latencies of 65, 53 
(p = 0.058), and 56.5 (p = 0.025) days for 0, 
BPA 25, and BPA 250, respectively. Although 
the BPA 25 group had a similar decrease in 
latency and an increase in tumor multiplicity 
(p = 0.131), neither of these changes reached 
statistical significance. Histopathologic evalua-
tion of these tumors revealed no changes in the 
carcinoma score, tumor burden, or length of 
time in the study for any treatment group (data 
not shown).
Apoptosis and cell proliferation. Previous 
reports have shown that exposure to BPA 
during the perinatal period through subcuta-
neously implanted pumps can lead to long-
lasting effects on cell turnover (Durando et al. 
2007; Munoz-de-Toro et al. 2005). Therefore, 
we assessed the rate of cellular proliferation 
and apoptosis in the structure most suscep-
tible to mammary carcinogenesis, the TEB. 
Interestingly, cell proliferation in TEBs of 
50-day-old but not 21-day-old rats was signifi-
cantly increased in those animals lactationally 
exposed to BPA 250 (p < 0.001; Figure 2). 
Equally important, apoptosis was significantly 
decreased in the mammary gland of 50-day-old 
but not 21-day-old BPA 250 rats (p = 0.001).
Akt and phosphorylated Akt (pAkt). 
Because of the statistically significant decrease 
in apoptosis in adult BPA 250 rats, we meas-
ured the expression of several proteins com-
monly linked to apoptosis. At 50 days of 
age, Akt (p = 0.001) and pAkt (p = 0.050) 
were significantly different between exposure 
groups, with each protein showing nearly a 
2-fold increase over control expression lev-
els [Figure 3; see also Supplemental Material, 
Figure 1 (available online at http://www.
ehponline.org/members/2009/11751/suppl.
pdf)]. Expressions of Bad, phosphorylated 
Bad, Bcl-2, caspase 2, caspase 3, and caspase 9 
Figure 1. DMBA  induced  mammary  tumors 
(mean ± SE) in rats exposed lactationally to BPA. 
p-Values reflect comparison with control.
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Figure 2. Cell proliferation and apoptosis in mammary glands of 50-day-old BPA 250 rats. (A) Ki-67 expression as an indicator of cell proliferation (left) and the 
TUNEL assay as measure of apoptosis (right). TEBs from five biologically distinct samples (n = 5) were analyzed per treatment. Magnification, 40×; bar = 100 µm. 
(B) Index values (mean ± SE) as a percentage of the control group. (C) Results [no. (%)] of cell proliferation and apoptosis analyses. 
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were not significantly different. Furthermore, 
none of these proteins was differentially regu-
lated at 21 days of age, suggesting that pro-
tein expression and activity of Akt were latent 
effects from BPA exposure.
Sex steroid receptors, SRCs, and growth 
factor receptors. Given the statistically signifi-
cant increase in cell proliferation in mammary 
TEBs of 50-day-old offspring exposed lacta-
tionally to BPA, we assessed proteins implicated 
in cellu  lar proliferation. Primarily because of 
BPA’s reported weakly estrogenic effects, we 
initially focused on sex steroid receptors. We 
found that BPA-exposed females exhibited an 
up-regulation of PR-A of 54% compared with 
control [p = 0.02; Figure 4; see Supplemental 
Material, Figure 1 (http://www.ehponline.org/
members/2009/11751/suppl.pdf)]. Because 
PR-A is a known down  stream target of estro-
gen signaling, we also assessed the expression 
of coregulator proteins known to play a role 
in increased estrogen signaling and breast can-
cer. We found all three members of the p160 
family of SRC proteins, SRC-1 (p = 0.001), 
SRC-2 (p = 0.003), and SRC-3 (p < 0.001), 
to be significantly up-regulated in response to 
lactational exposure to BPA [Figure 4; see also 
Supplemental Material, Figure 1 (http://www.
ehponline.org/members/2009/11751/suppl.
pdf)]. Finally, a correlation has been docu-
mented between SRC expression and expression 
of the erbB family of tyrosine kinases. Although 
we noted no significant differences for erbB1 
(epidermal growth factor receptor) or erbB2 
(neu), we found a significant increase in erbB3 
expression (p = 0.01). 
Discussion
We report for the first time that oral exposure 
of rats to BPA via lactating dams significantly 
reduced tumor latency and increased tumor 
multiplicity in offspring in a dose-dependent 
manner in a DMBA model of rodent mam-
mary carcinogenesis. In the design of these 
studies to determine if BPA would predispose 
for mammary cancer, our first considerations 
were model, route and timing of exposure, 
and dose.
Although no model is perfect, we chose rats 
because of the reasonable similarity in mammary 
gland development and use of the chemically 
induced mammary cancer model for tumori-
genesis studies (Russo IH and Russo 1978; 
Russo et al. 1990). Because humans are exposed 
to BPA primarily by ingestion, we treated rats 
orally as opposed to injections or subcutaneous 
implants. This takes into consideration metabo-
lism and disposition. Because timing of expo-
sure is important to target organ toxicity and 
mecha  nism of action, we selected the neonatal/
prepubertal period for these studies. In choos-
ing the doses, we took into considera  tion a) the 
reports of estimated exposures of preschool chil-
dren BPA at 52–74 ng/kg bw/day (Wilson et al. 
2007); b) that the European Commission esti-
mated BPA exposure in infants (3–6 months 
of age) at 0.2–8.3 µg/kg bw/day (European 
Food Safety Authority 2006); and c) that the 
European Union estimated exposure in infants 
(1–6 months of age) at 7–8 µg/kg bw/day 
(European Commission 2003). Accordingly, we 
chose to treat the dams with a low dose of BPA 
(25 µg/kg bw/day, 50% of the U.S. EPA’s daily 
oral reference dose of 50 µg/kg bw/day) and a 
dose that was 10-fold higher than the low dose 
(250 µg/kg/day). Furthermore, we exposed the 
offspring to significantly less BPA than the dose 
administered to the dams because of dilution 
factors resulting from maternal and fetal metab-
olism and disposition, lactation, and number of 
offspring. Although the actual blood and tissue 
concentrations have yet to be determined in our 
animals, we surmise that the effects reported in 
the present study are a result of low exposures 
to BPA. Likewise, it is possible that the effects 
of BPA could be on the dam, which could alter 
hormones and composition of the milk and 
consequently the offspring, issues that we have 
not investigated.
Our mammary cancer findings are sup-
ported by other in vivo studies. Durando 
et al. (2007) showed that prenatal exposure 
to BPA (via an osmotic pump, which equates 
to subcutaneous administration) coupled 
to a sub  carcinogenic dose of N-nitroso-N-
methylurea resulted in an increased percent-
age of pre  neoplastic and neo  plastic lesions in 
the mammary gland. Similarly, Murray et al. 
(2007) found that exposure to BPA during 
the pre  natal period through an osmotic pump 
resulted in the development of carcinoma 
in situ in the mammary gland even in the 
absence of an additional carcinogen. Although 
these studies used different periods of expo-
sure, route of administration, and end point, 
they still provide support for our findings and 
add to the growing literature that implicates 
a detrimental role for early BPA exposure in 
mammary cancer susceptibility.
Our cell proliferation and apoptosis stud-
ies showed that no signifi  cant effects stemmed 
from direct BPA exposure (at 21 days of age). 
However, delayed effects did occur. At 50 days 
of age, > 4 weeks after discontinuing treatment 
with BPA, cell proliferation was significantly 
increased, and apoptosis was significantly 
decreased, in the mammary glands of rats lac-
tationally exposed to BPA. Females lactationally 
exposed to BPA had a proliferation to apopto-
sis ratio twice that of control rats in the struc-
tures most susceptible to carcinogenesis in the 
mammary gland, the TEBs (Russo J and Russo 
1978). Subsequent Western blotting analysis 
revealed that a key regulator of apoptosis, Akt 
and the biologically active pAkt, was signifi-
cantly up-regulated. These findings were not 
unexpected given that both pre  natal and peri-
natal exposures to BPA in rodents (via osmotic 
pumps) have been reported to cause decreased 
apoptosis in the mammary gland (Durando 
et al. 2007; Munoz-de-Toro et al. 2005). 
With the balance of cell turnover disrupted 
so severely, such a situation could provide an 
environment more susceptible to exposure to 
a secondary carcinogen, such as DMBA. The 
significant increase in proliferation observed 
Figure 3. Akt and pAkt protein expression in mam-
mary glands of 50-day-old SO controls and BPA 250 
rats detected by Western blot analysis [see also 
Supplemental Material, Figure 1 (http://www.ehpon-
line.org/members/2009/11751/suppl.pdf)]. For each 
treatment group, n = 8. Values shown are mean 
density ± SE as a percentage of control group. 
*p = 0.05, and **p = 0.001, compared with control. 
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Figure 4. ER-α, PR-A, PR-B, SRC-1, SRC-2, SRC-3, erbB2, and erbB3 protein expression in mammary glands 
of 50-day-old SO control and BPA 250 rats detected by Western blot analysis [see also Supplemental 
Material, Figure 1 (http://www.ehponline.org/members/2009/11751/suppl.pdf)]. For each treatment group, 
n = 8. Values shown are mean density ± SE as a percentage of the control group. 
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in our study, but not in other studies, may be 
a function of differing BPA exposure schemes 
or routes of administration (i.e., post  natal vs. 
pre  natal exposures, oral administration vs. sub-
cutaneous implants, dose, etc.) that can affect 
metabolism and disposition.
By most accounts, BPA’s mechanism of 
action is thought to revolve around its weak 
estrogenic activity. Hence, we evaluated the 
effects of lactational exposure to BPA on sex 
steroid receptors in the mammary gland using 
Western blot analysis. Although we observed 
no significant change for ER-α or PR-B, we 
observed a significant increase for PR-A. This 
finding is supported by the work of Munoz-
de-Toro et al. (2005), who found an increased 
percentage of cells expressing PR in the mam-
mary gland after peri  natal BPA treatment. PR 
has been highly implicated in breast cancer by 
functioning as the nuclear receptor for the sex 
hormone progesterone. Recent work has indi-
cated that the two isoforms of PR function in 
distinct manners and are induced by differ-
ing stimuli. PR-A is the predominant isoform 
expressed in the pubertal, virgin mammary 
gland and is vital to side branching (Aupperlee 
et al. 2005). Studies of transgenic mice engi-
neered to over  express PR-A have demonstrated 
abnormalities in the mammary gland, includ-
ing the development of hyperplastic lesions 
with a dis  organized basement membrane 
and reduced cell-to-cell adhesion (Shyamala 
et al. 1998). Interestingly, PR-A has also been 
reported to be induced by estradiol in Sprague 
Dawley rats (Kariagina et al. 2007).
To ensure that increased expression of 
PR-A was not a result of lactational BPA caus-
ing increased concentrations of circulating 
estradiol, we measured hormone concentrations 
in rats at 50 days of age. We found no signifi-
cant difference between the BPA-exposed and 
control groups, confirming that sex hormone 
concentrations were not altered by lactational 
BPA exposure. However, no significant changes 
that we observed manifested before the onset of 
puberty. One potential explanation is that early 
exposure to BPA increased the sensitivity of the 
mammary gland to the hormones of puberty. 
We found increased cell proliferation and PR-A 
expression coupled with decreased apoptosis 
long after the original exposure to BPA ceased. 
It is possible that early BPA exposure imprints 
or sensitizes the rat to the effects of post  pubertal 
hormone. Then, as the concentrations of circu-
lating sex hormones increase post  pubertally, the 
indirect effects of BPA manifest. This theory has 
recently been suggested by Wadia et al. (2007), 
who showed that ovariectomized CD-1 mice 
pre  natally exposed to BPA displayed a signifi-
cantly heightened response in the mammary 
gland after an estrogenic stimulus.
A potential mechanism involved in a 
heightened response to estrogen is through 
SRC proteins. SRCs function to accelerate 
hormone-bound nuclear-receptor–induced tran-
scription through weak histone acetyl  transferase 
activity and by recruiting chromatin modifica-
tion enzymes to the promoter/enhancer regions 
of target genes. The endogenous milieu of coreg-
ulator proteins in the target tissue are thought to 
have great impact on the activation of nuclear 
receptors, such as ER and PR, and be the basis of 
chemotherapeutic resistance and tissue-specific 
function of selective ER modulators (Schiff et al. 
2003). We found the expression of the p160 
family of SRC proteins (SRC-1, SRC-2, and 
SRC-3) to be dramatically increased at 50 days 
of age after lactational exposure to BPA.
Descriptions of SRC activity, as reported 
through transgenic mouse models, provide a 
close correlation with many of the reported 
effects of early exposure to BPA. Alterations in 
morphology, such as decreased side branching, 
decreased ductal elongation, and increased alve-
ologenesis, have been reported in mice deficient 
in SRC-1 and SRC-3 (Xu et al. 1998, 2000). 
It seems plausible that increased expression of 
the SRCs in the mammary glands, as reported 
in our study, would confer a greater incidence 
of side branching and alveologenesis. Indeed, 
mice over  expressing SRC-3/AIB1 showed a 
greater degree of ductal branching (Torres-
Arzayus et al. 2004). Three independent 
reports on early BPA exposure have described 
similar morphologic abnormalities, such as 
increased side branching and alveologenesis, 
in the mammary gland (Markey et al. 2001, 
2005; Munoz-de-Toro et al. 2005). Knocking 
out SRC-3/AIB1 in mice has been shown to 
confer resistance to DMBA-induced mammary 
cancer, resulting in an increased tumor latency, 
reduced multiplicity, and slower growth rate 
(Kuang et al. 2005). Our results demonstrate 
that lactational BPA exposure results in a sig-
nificant increase in DMBA-induced mam-
mary cancer susceptibility at a time when the 
local environment of the mammary gland has 
drastically up-regulated expression of all of the 
SRCs. Likewise, transgenic mice engineered 
to over  express SRC-3 exhibit an increased 
susceptibility to mammary cancer, develop-
ing mammary hypertrophy, hyperplasia, and 
malignant tumor formation after a long latency 
period (Torres-Arzayus et al. 2004). Prenatal 
BPA has been shown to cause an increase in 
premalignant and/or malignant lesions in the 
mammary glands of rats during adulthood 
when given alone or in concert with a sub-
carcinogenic dose of N-nitroso-N-methylurea 
(Durando et al. 2007; Murray et al. 2007). 
SRC-3/AIB1-deficient mice also show reduced 
Akt activity, whereas SRC-3/AIB1–over-
expressing mice show increased Akt activation 
and reduction in apoptosis in the mammary 
gland and in mammary tumors (Kuang et al. 
2005; Torres-Arzayus et al. 2004). We report 
here that lactational BPA is able to up-regulate 
Akt expression/activation and down-regulate 
apoptosis in the mammary gland during adult-
hood. Finally, Xu et al. (2007) described peri-
natal exposure to BPA in Sprague Dawley rats 
causing a significant increase in SRC-1 mRNA 
and protein in the hippocampus of male pups. 
A relationship has been established in the 
literature between the SRCs, HER2/erbB2, 
and the Akt signaling pathway. One study 
reported SRC-1 to be over  expressed in 46% 
of HER2-positive breast tumors but in only 
6% of HER2-negative breast tumors (Fleming 
et al. 2004). Bouras et al. (2001) reported a 
positive correlation between the expression 
of SRC-3, HER2, and p53. Although HER2 
breast tumors are frequently cited as resulting 
in shorter disease-free survival, coupling HER2 
over  expression with SRC-3 over  expression has 
been reported to worsen the prognosis fur-
ther, adding a greater risk of refractory dis-
ease (Kirkegaard et al. 2007; Mc Ilroy et al. 
2006; Osborne et al. 2003). SRC-3/AIB1 
has also been shown to control the activity of 
both erbB1 and HER2 (erbB2) (Lahusen et al. 
2007). Down-regulating erbB3 through small 
interfering RNA reduces Akt activity (Liu et al. 
2007). These results suggest that coactivator 
proteins may serve as essential mediator pro-
teins, linking crosstalk between growth factors 
and sex steroid signaling pathways.
Although we noted no changes between 
treatment groups in the expression of erbB1, 
erbB2, or erbB4, we found a significant up-
regulation for erbB3. erbB3, despite lacking a 
catalytic domain, has been reported to be the 
preferred dimerization partner for erbB2. This 
pairing has also been reported to induce the 
most mitogenic response that preferentially 
signals through the Akt pathway (Karamouzis 
et al. 2007). Although over  expression of erbB3 
alone may induce mammary carcino  genesis, 
over  expression of both erbB2 and erbB3 has 
been observed frequently in a transgenic mouse 
model that over  expresses the wild-type erbB2 
protein, and in human breast tumor samples 
(Karamouzis et al. 2007). This dual over-
expression has been linked to more aggressive 
disease and increased development of drug-resis-
tant cancer. Thus, although we did not observe 
the up-regulation of erbB2 at this specific time 
point (50 days of age), an up-regulation of 
erbB3 could provide ample access to a binding 
partner for erbB2 and provide a local environ-
ment more prone for cancer development.
Conclusion
The data we present here provide the first evi-
dence that maternal exposure to BPA during 
lactation decreased time to first tumor latency 
and increased the number of DMBA-induced 
mammary tumors in female offspring. We 
conclude that increased cell proliferation and 
decreased apoptosis at the time of DMBA 
administration play a vital role in BPA’s 
mechanism of action. Furthermore, we believe Bisphenol A increases mammary cancer in rats
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that these effects are, at least in part, medi-
ated through the increased expression of erbB3 
and the p160 family of SRCs (SRC-1, SRC-2, 
and SRC-3/AIB1) and increased Akt activity. 
Interestingly, the published observations of 
early exposure to BPA overlap well with the 
reported phenotypes of transgenic mouse mod-
els of SRC over  expression and counter models 
of SRC deficiency. However, not only do the 
alterations reported here provide an explana-
tion of enhanced mammary carcinogenesis 
after lactational treatment with BPA, but they 
also warn of the potential for developing more 
aggressive and refractory forms of breast cancer. 
In coculturing non  malignant, random peri-
areolar fine-needle aspirates from the contra-
lateral breast of women with breast cancer, 
Dairkee et al. (2008) found that physio  logic 
doses of estrogen and progesterone coupled to 
BPA produced a gene signature profile that was 
associated with breast tumors with high patho-
logic grade, greater tumor size, and shorter dis-
ease-free patient survival. Increased expression 
of erbB2, erbB3, the SRCs, and Akt activation 
and have been linked with tamoxi  fen resistance 
(Bouras et al. 2001; Kirkegaard et al. 2007; 
Mc Ilroy et al. 2006; Osborne et al. 2003). 
In breast cancer patients, high SRC-3/AIB1 
expression is associated with HER2 overexpres-
sion, tamoxifen resistance, and higher mor-
tality. If these effects found in rodents carry 
over to humans, even small, seemingly harm-
less exposures of BPA early in life could be 
detri  mental and play a role in increased breast 
cancer susceptibility as well as the ability of a 
tumor to become resistant to therapy.
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